

Lars Østergaard er uddannet læge fra 1990 og blev speciallæge i infektionsmedicin i år 2000.

Lars opnåede sin ph.d. grad i 1995 og forsvarede sin doktordisputats i 1999.

Han har de sidste fem år været professor i infektionssygdomme ved Aarhus Universitetshospital og har bidraget til flere hundrede videnskabelige artikler samt bedømt og vejledt adskillige videnskabelige afhandlinger.

Rejsemedicinske publikationer:

1: Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. Toft L, Tolstrup M, Storgaard M, Ostergaard L, Søgaard OS. Sex Health. 2014 Dec;11(6):511-23

2: Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Østergaard L, Søgaard OS. Hum Vaccin Immunother. 2014 May;10(5):1147-54.

3: Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, Østergaard L, Søgaard OS. J Infect Dis. 2014 Apr 15;209(8):1165-73.

4: Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial. HSV-040 Study Group, Abu-Elyazeed RR, Heineman T, Dubin G, Fournau M, Leroux-Roels I, Leroux-Roels G, Richardus JH, Ostergaard L, Diez-Domingo J, Poder A, Van Damme P, Romanowski B, Blatter M, Silfverdal SA, Berglund J, Josefsson A, Cunningham AL, Flodmark CE, Tragiannidis A, Dobson S, Olafsson J, Puig-Barbera J, Mendez M, Barton S, Bernstein D, Mares J, Ratner P. Vaccine. 2013 Dec 9;31(51):6136-43.

5: Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis--an observational cohort study. Skov Dalgaard L, Fassel U, Østergaard LJ, Jespersen B, Schmeltz Søgaard O, Jensen-Fangel S. BMC Nephrol. 2013 Jul 8;14:137. doi: 10.1186/1471-2369-14-137.

6: Leukocyte transcript alterations in West-African girls following a booster vaccination with diphtheria-tetanus-pertussis vaccine. Orntoft NW, Thorsen K, Benn CS, Lemvik G, Nanque JR, Aaby P, Ostergaard L, Agergaard J. Scand J Clin Lab Invest. 2013 May 13.

7: Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. Winckelmann AA, Munk-Petersen LV, Rasmussen TA, Melchjorsen J, Hjelholt TJ, Montefiori D, Østergaard L, Søgaard OS, Tolstrup M. PLoS One. 2013 Apr 26;8(4):e62074.

8: Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Østergaard L, Van der Wielen M, Bianco V, Miller JM. *Int J Infect Dis.* 2013 Mar;17(3):e173-6.

9: Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. Rasmussen TA, Jørgensen MR, Bjerrum S, Jensen-Fangel S, Støvring H, Østergaard L, Søgaard OS. *BMJ.* 2012 Sep 17;345:e5823.

1: The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults. Johannesson TG, Søgaard OS, Tolstrup M, Petersen MS, Bernth-Jensen JM, Østergaard L, Erikstrup C. *PLoS One.* 2012;7(7):e42307.

11: TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. Offersen R, Melchjorsen J, Paludan SR, Østergaard L, Tolstrup M, Søgaard OS. *Hum Vaccin Immunother.* 2012 Aug;8(8):1042-7.

12: Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice. Jensen KM, Melchjorsen J, Dagnaes-Hansen F, Sørensen UB, Laursen RR, Østergaard L, Søgaard OS, Tolstrup M. *Infect Immun.* 2012 May;80(5):1744-52.

13: A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial. Østergaard L, Silfverdal SA, Berglund J, Flodmark CE, West C, Bianco V, Baine Y, Miller JM. *Vaccine.* 2012 Jan 17;30(4):774-83.

14: Diphtheria-tetanus-pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomised trial from Guinea-Bissau. Agergaard J, Nante E, Poulstrup G, Nielsen J, Flanagan KL, Østergaard L, Benn CS, Aaby P. *Vaccine.* 2011 Jan 10;29(3):487-500.

15: The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. Pedersen RH, Lohse N, Østergaard L, Søgaard OS. *HIV Med.* 2011 Jul;12(6):323-33.

16: Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. Søgaard OS, Schønheyder HC, Bukh AR, Harboe ZB, Rasmussen TA, Ostergaard L, Lohse N. *AIDS.* 2010 Jun 1;24(9):1315-22.

17: Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Søgaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, Schønheyder HC, Østergaard L. *Clin Infect Dis.* 2010 Jul 1;51(1):42-50.